SenzaGen AB 2024 AR2
The report highlights a strong financial year for SenzaGen in 2024, with total revenue increasing by 16% to SEK 58 million and EBITDA losses halved. The company's core non-animal skin sensitization testing platform, GARD®, achieved record sales growth of 53%, driven by a 30% increase in paying customers. SenzaGen expanded its market presence in the US through a licensing agreement with IIVS and continued to strengthen its partnerships with major industry players like L'Oréal and RIFM. Additionally, the company advanced its sustainability efforts by aligning with the UN Global Compact and several Sustainable Development Goals, promoting ethical, non-animal testing alternatives.
Company: SenzaGen AB
Sector: Professional & technical services
Country: Sweden
Year: 2024
Type: AR2
Pages: 59
Back to company
SenzaGen AB
Annual Report
The report highlights a strong financial year for SenzaGen in 2024, with total revenue increasing by 16% to SEK 58 million and EBITDA losses halved. The company's core non-animal skin sensitization testing platform, GARD®, achieved record sales growth of 53%, driven by a 30% increase in paying customers. SenzaGen expanded its market presence in the US through a licensing agreement with IIVS and continued to strengthen its partnerships with major industry players like L'Oréal and RIFM. Additionally, the company advanced its sustainability efforts by aligning with the UN Global Compact and several Sustainable Development Goals, promoting ethical, non-animal testing alternatives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees